未来制药企业之间的竞争是商业模式竞争

2017-06-16 医药史立臣 MedSci原创

单纯的卖产品不叫商业模式,而中国大部分药企就是在卖产品。中国医药行业很多企业把代理模式、经销模式、控销模式、分销模式等叫作商业模式,其实这是营销模式,不是真正的商业模式。

现在的概念和定义很多,比如B2B、B2C、O2O等。笔者比较认可的商业模式定义是:为实现客户价值最大化,把能使企业运行的内外各要素整合起来,形成一个完整的、高效率的、具有独特核心竞争力的运行系统,并通过最优配置和组合的形式满足客户需求、实现客户价值,同时使企业运营系统达成持续赢利目标的整体解决方案。除了复杂的定义以外,其实商业模式说白了就是赚钱模式或者盈利模式。第三方医药服务平台麦斯康莱(maxcolla)创始人史立臣认为,单纯的卖产品不叫商业模式,而中国大部分药企就是在卖产品。中国医药行业很多企业把代理模式、经销模式、控销模式、分销模式等叫作商业模式,其实这是营销模式,不是真正的商业模式。营销模式可以根据产品的不同进行个性化的变化或者修正,但商业模式一旦固定就很难短期改变。制药企业的商业模式也有一些成功范例,只是形式比较少。较为典型的是广告拉动模式,比如哈药集团依靠广告营销树立起几个优秀的OTC品牌、仁和集团可立克、江中制药的健胃消食片等品牌。还有被称为业界PE的复星医药的投资运营模式。复星医药凭借这个独特的商业模式把一个名不见经传的小药企做成了综合性集团公司。还有以新药研发为主的研

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1771742, encodeId=23fc1e71742a1, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Thu Apr 26 22:19:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456087, encodeId=1139145608e1c, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596326, encodeId=61531596326ad, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599415, encodeId=35f21599415b5, content=<a href='/topic/show?id=08c14006ead' target=_blank style='color:#2F92EE;'>#商业模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40067, encryptionId=08c14006ead, topicName=商业模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fdc18711141, createdName=lqrandywkz, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211692, encodeId=e40a211692b3, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Jun 17 00:10:45 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1771742, encodeId=23fc1e71742a1, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Thu Apr 26 22:19:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456087, encodeId=1139145608e1c, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596326, encodeId=61531596326ad, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599415, encodeId=35f21599415b5, content=<a href='/topic/show?id=08c14006ead' target=_blank style='color:#2F92EE;'>#商业模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40067, encryptionId=08c14006ead, topicName=商业模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fdc18711141, createdName=lqrandywkz, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211692, encodeId=e40a211692b3, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Jun 17 00:10:45 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-18 hyf030
  3. [GetPortalCommentsPageByObjectIdResponse(id=1771742, encodeId=23fc1e71742a1, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Thu Apr 26 22:19:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456087, encodeId=1139145608e1c, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596326, encodeId=61531596326ad, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599415, encodeId=35f21599415b5, content=<a href='/topic/show?id=08c14006ead' target=_blank style='color:#2F92EE;'>#商业模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40067, encryptionId=08c14006ead, topicName=商业模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fdc18711141, createdName=lqrandywkz, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211692, encodeId=e40a211692b3, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Jun 17 00:10:45 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1771742, encodeId=23fc1e71742a1, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Thu Apr 26 22:19:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456087, encodeId=1139145608e1c, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596326, encodeId=61531596326ad, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599415, encodeId=35f21599415b5, content=<a href='/topic/show?id=08c14006ead' target=_blank style='color:#2F92EE;'>#商业模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40067, encryptionId=08c14006ead, topicName=商业模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fdc18711141, createdName=lqrandywkz, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211692, encodeId=e40a211692b3, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Jun 17 00:10:45 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1771742, encodeId=23fc1e71742a1, content=<a href='/topic/show?id=62754005931' target=_blank style='color:#2F92EE;'>#商业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40059, encryptionId=62754005931, topicName=商业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd6238344589, createdName=zhangxingru, createdTime=Thu Apr 26 22:19:00 CST 2018, time=2018-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456087, encodeId=1139145608e1c, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596326, encodeId=61531596326ad, content=<a href='/topic/show?id=31693238980' target=_blank style='color:#2F92EE;'>#制药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32389, encryptionId=31693238980, topicName=制药企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2c818366159, createdName=listen324, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1599415, encodeId=35f21599415b5, content=<a href='/topic/show?id=08c14006ead' target=_blank style='color:#2F92EE;'>#商业模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40067, encryptionId=08c14006ead, topicName=商业模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fdc18711141, createdName=lqrandywkz, createdTime=Sun Jun 18 06:19:00 CST 2017, time=2017-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211692, encodeId=e40a211692b3, content=学习了谢谢分享。, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Sat Jun 17 00:10:45 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 184****9840

    学习了谢谢分享。

    0

相关资讯

新营销组织构建,再不抓紧就来不及了

制药企业就需要对现有的营销组织进行改革和调整,以适应新形势的变化需要,否则老马拉旧车,在新的道路上会走得很艰难。

疾病产品群:医药营销真正的利器

药企就要考虑怎样去和诸多药企进行同层次竞争,突出单品很容易被模仿和超越,但是,产品群就很难被超越,甚至模仿的难度都很大。

以市场为导向构建新营销体系

单纯的把所有资源都投入到营销领域中去,结果造成了过度营销。

新营销体系构建的基础是什么?

对制药企业来说,产品是生存和发展的基础

一致性评价,构建产品战略的更佳时机

仿制药一致性评价的推进,正是药企制定产品战略的最佳时机。

原创:高考后,17岁的她吞下了一瓶相思豆......

相思豆有剧毒,你们知道吗?